Ligand Pharms Inc Cvr
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more
Market Cap & Net Worth: Ligand Pharms Inc Cvr (LGNDZ)
Ligand Pharms Inc Cvr (PINK:LGNDZ) has a market capitalization of $28.53 ($28.53) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #42043 globally and #13634 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ligand Pharms Inc Cvr's stock price $0.00 by its total outstanding shares 9509 (9.51K).
Ligand Pharms Inc Cvr Market Cap History: 2015 to 2025
Ligand Pharms Inc Cvr's market capitalization history from 2015 to 2025. Data shows change from $34.23 to $28.53 (-10.97% CAGR).
Ligand Pharms Inc Cvr Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ligand Pharms Inc Cvr's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Ligand Pharms Inc Cvr's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Ligand Pharms Inc Cvr's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $34.23 | $71.91 Million | -$184.27 Million | 0.00x | N/A |
| 2016 | $25.67 | $108.97 Million | $18.29 Million | 0.00x | 0.00x |
| 2017 | $71.32 | $141.10 Million | $101.91 Million | 0.00x | 0.00x |
| 2018 | $52.30 | $251.45 Million | $143.32 Million | 0.00x | 0.00x |
| 2019 | $20.92 | $120.28 Million | $629.30 Million | 0.00x | 0.00x |
| 2020 | $54.20 | $186.42 Million | -$2.98 Million | 0.00x | N/A |
| 2021 | $71.32 | $241.54 Million | $57.14 Million | 0.00x | 0.00x |
| 2022 | $57.05 | $196.25 Million | -$33.36 Million | 0.00x | N/A |
| 2023 | $42.79 | $131.31 Million | $52.15 Million | 0.00x | 0.00x |
| 2024 | $36.13 | $167.13 Million | $9.07 Million | 0.00x | 0.00x |
Competitor Companies of LGNDZ by Market Capitalization
Companies near Ligand Pharms Inc Cvr in the global market cap rankings as of March 19, 2026.
Key companies related to Ligand Pharms Inc Cvr by market ranking:
- ALLIANZ TECHNO.TR.LS-025 (F:28X): Ranked #42034 globally with a market cap of $58.04K USD ( €56.54K EUR).
- 4by4 Inc (KQ:389140): Ranked #42035 globally with a market cap of $57.92K USD ( ₩84.81 Million KRW).
- SILO WELLNESS INC. (F:3K7A): Ranked #42044 globally with a market cap of $57.71K USD ( €56.23K EUR).
- Kardan NV (TA:KRNV): Ranked #42045 globally with a market cap of $57.69K USD ( ILA21.52 Million ILA).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #42034 | ALLIANZ TECHNO.TR.LS-025 | F:28X | $58.04K | €6.15 |
| #42035 | 4by4 Inc | KQ:389140 | $57.92K | ₩9280.00 |
| #42044 | SILO WELLNESS INC. | F:3K7A | $57.71K | €0.00 |
| #42045 | Kardan NV | TA:KRNV | $57.69K | ILA2.80 |
Ligand Pharms Inc Cvr Historical Marketcap From 2015 to 2025
Between 2015 and today, Ligand Pharms Inc Cvr's market cap moved from $34.23 to $ 28.53, with a yearly change of -10.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $28.53 | -21.05% |
| 2024 | $36.13 | -15.56% |
| 2023 | $42.79 | -25.00% |
| 2022 | $57.05 | -20.00% |
| 2021 | $71.32 | +31.58% |
| 2020 | $54.20 | +159.09% |
| 2019 | $20.92 | -60.00% |
| 2018 | $52.30 | -26.67% |
| 2017 | $71.32 | +177.78% |
| 2016 | $25.67 | -25.00% |
| 2015 | $34.23 | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ligand Pharms Inc Cvr was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.53 USD |
| MoneyControl | $28.53 USD |
| MarketWatch | $28.53 USD |
| marketcap.company | $28.53 USD |
| Reuters | $28.53 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.